# Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

> **NCT00301834** · PHASE2 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 35 (actual)

## Conditions studied

- Congenital Amegakaryocytic Thrombocytopenia
- Diamond-blackfan Anemia
- Leukemia
- Myelodysplastic Syndromes
- Severe Congenital Neutropenia

## Interventions

- **BIOLOGICAL:** alemtuzumab
- **DRUG:** busulfan
- **DRUG:** cyclosporine
- **DRUG:** fludarabine phosphate
- **DRUG:** methotrexate
- **DRUG:** methylprednisolone
- **PROCEDURE:** allogeneic bone marrow transplantation
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation
- **PROCEDURE:** umbilical cord blood transplantation

## Key facts

- **NCT ID:** NCT00301834
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2017-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00301834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00301834, "Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00301834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*